erlotinib
Sign in to saveErlotinib, sold under the brand name Tarceva among others, is a medication used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. Specifically it is used for NSCLC with mutations in the epidermal growth factor receptor (EGFR) — either an exon 19 deletion (del19) or exon 21 (L858R) substitution mutation — which has spread to other parts of the body. It is taken by mouth.
Key facts
- Drug.verifiedrevid
- 464189825
- Drug.image
- Erlotinib.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 250
- Drug.image2
- Erlotinib-1m17-3D-balls.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Tarceva
- Drug.MedlinePlus
- a605008
- Drug.DailyMedID
- Erlotinib
- Drug.pregnancy_AU
- C
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- EB02
- Drug.legal_AU
- S4
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.bioavailability
- 59%
- Drug.protein_bound
- 95%
via Wikipedia infobox
Article
12 sectionsContents
- Medical uses
- Lung cancer
- Pancreatic cancer
- Resistance to treatment
- Side effects
- Common
- Rare
- Interactions
- Mechanism
- Society and culture
- References
- External links
Erlotinib, sold under the brand name Tarceva among others, is a medication used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. Specifically it is used for NSCLC with mutations in the epidermal growth factor receptor (EGFR) — either an exon 19 deletion (del19) or exon 21 (L858R) substitution mutation — which has spread to other parts of the body. It is taken by mouth.
Common side effects include rash, diarrhea, muscle pain, joint pain, and cough. Serious side effects may include lung problems, kidney problems, liver failure, gastrointestinal perforation, stroke, and corneal ulceration. Use in pregnancy may harm the baby. It is a receptor tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).